A Safety, Tolerability, and Efficacy Study of VX-880 in Participants ...
Aug 1, 2025 · This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe …
VX-548 is being developed for the treatment of pain. VX-548 is a NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. Clinical data from Phase 1 studies in healthy subjects and …
Overall Design: This is a randomized, investigator- and participant-blind, sponsor-open, placebo-controlled, first-in-human study to assess safety, tolerability, PK and PD of single ascending oral …
JNJ-61186372(amivantamab) and JNJ-73841937 (lazertinib) *Janssen Research & Development is a global organization that operates through different legal entities in various countries/territories. …
A VX-445 dose of 200 mg qd was selected for the current study based on an assessment of the benefit-risk profile from the ongoing Phase 2 Study VX16-445-001 (Study 445-001) Parts D and E.
You are being asked to take part in a research study at the National Institutes of Health (NIH). Members of the study team will talk with you about the information described in this document. Some people …
- [PDF]
redacted Protocol
An internal Unblinded Review Committee (URC) of AstraZeneca representatives is set up for this study for ongoing safety monitoring and reviewing the unblinded interim results. In addition to general …
Research Study Informed Consent Document – Phase 2 Study Title for Participants: Testing the addition of an anti-cancer drug, Berzosertib (M6620, VX-970), to the usual treatments (carboplatin and …
A Phase I Trial of Lymphodepletion plus Adoptive Cell Therapy with …
A Phase I Trial of Lymphodepletion plus Adoptive Cell Therapy with High-Dose IL-2 in Adolescent and Young Adult Patients with Soft Tissue Sarcoma
Results from th1S study will provide Information on the long-tenn safety of TC treatment with VX-445/TEZ/IVA in subjects with CF who are 12 years of age and older and homozygous or …
The details of the agent M6620 (VX-970, berzosertib) are described below. Between the months of December 2014 and February 2015, a series of weekly teleconferences with multiple additional …
For subjects <18 years of age (age on the date of informed consent/assent in the parent study) not eligible for further treatment with VX-661 and ivacaftor or who choose not to continue treatment, …